The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?

American Journal of Obstetrics and Gynecology

Volumn 199, Issue 3, 2008, Pages 215-223

  Nossov, Vladimir ^a   Amneus, Malaika ^a   Su, Feng ^a   Lang, Jennifer ^a   Janco, Jo Marie Tran ^a   Reddy, Srinivasa T ^a,c   Farias Eisner, Robin ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

markers; ovarian cancer; proteomics; screening

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; COLONY STIMULATING FACTOR 1; LYSOPHOSPHATIDIC ACID;

ANALYTIC METHOD; CLASSIFICATION AND REGRESSION TREE ANALYSIS; DOPPLER ECHOGRAPHY; EARLY DIAGNOSIS; HUMAN; INTERMETHOD COMPARISON; OVARY CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEOMICS; REVIEW; SCREENING TEST; ULTRASOUND;

APOLIPOPROTEIN A-I; CA-125 ANTIGEN; EPIDIDYMAL SECRETORY PROTEINS; FEMALE; HUMANS; MICRODISSECTION; OVARIAN NEOPLASMS; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL; ULTRASONOGRAPHY, DOPPLER, COLOR; VAGINA;

EID: 50349091687     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2008.04.009     Document Type: Review

References (95)

1. Wilson J.M., and Jungner Y.G. Principles and practice of mass screening for disease. Bol Oficina Sanit Panam 65 (1968) 281-393
2. Wilson J.M.G., and Jungner G. Principles and practice of screening for disease. WHO Chronicle 22 (1968) 473
3. Jacobs I., Davies A.P., Bridges J., et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ 306 (1993) 1030-1034
4. Jacobs I.J., and Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 3 (2004) 355-366
5. National Institutes of Health consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA 273 (1995) 491-497
6. Jacobs I. Overview-progress in screening for ovarian cancer. In: Sharp F., Blackett A., Berek J., and Bast R. (Eds). Ovarian cancer (1998), Isis Medical Media, Oxford (UK)
7. Ozols R., Rubin S., Thomas G., and Robboy S. Epithelial ovarian cancer. In: Hoskins W., and Young R. (Eds). Principles and practice of gynecologic oncology (2001), Williams and Wilkins, New York
8. Kabawat S.E., Bast Jr. R.C., Bhan A.K., Welch W.R., Knapp R.C., and Colvin R.B. Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol 2 (1983) 275-285
9. Nustad K., Bast Jr. R.C., Brien T.J., et al. Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine. Tumour Biol 17 (1996) 196-219
10. Lloyd K.O., Yin B.W., and Kudryashov V. Isolation and characterization of ovarian cancer antigen CA 125 using a new monoclonal antibody (VK-8): Identification as a mucin-type molecule. Int J Cancer 71 (1997) 842-850
11. Bast Jr. R.C., Klug T.L., St John E., et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309 (1983) 883-887
12. Kenemans P., van Kamp G.J., Oehr P., and Verstraeten R.A. Heterologous double-determinant immunoradiometric assay CA 125 II: Reliable second-generation immunoassay for determining CA 125 in serum. Clin Chem 39 (1993) 2509-2513
13. Canney P.A., Moore M., Wilkinson P.M., and James R.D. Ovarian cancer antigen CA125: A prospective clinical assessment of its role as a tumour marker. Br J Cancer 50 (1984) 765-769
14. Hogdall E.V., Christensen L., Kjaer S.K., et al. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study. Gynecol Oncol 104 (2007) 508-515
15. Zurawski Jr. V.R., Orjaseter H., Andersen A., and Jellum E. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: Relevance for early detection of ovarian cancer. Int J Cancer 42 (1988) 677-680
16. Helzlsouer K.J., Bush T.L., Alberg A.J., Bass K.M., Zacur H., and Comstock G.W. Prospective study of serum CA-125 levels as markers of ovarian cancer. JAMA 269 (1993) 1123-1126
17. Skates S.J., Menon U., MacDonald N., et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol 21 (2003) 206s-210s
18. Valentin L., Skoog L., and Epstein E. Frequency and type of adnexal lesions in autopsy material from postmenopausal women: Ultrasound study with histological correlation. Ultrasound Obstet Gynecol 22 (2003) 284-289
19. Bailey C.L., Ueland F.R., Land G.L., et al. The malignant potential of small cystic ovarian tumors in women over 50 years of age. Gynecol Oncol 69 (1998) 3-7
20. Levine D., Gosink B.B., Wolf S.I., Feldesman M.R., and Pretorius D.H. Simple adnexal cysts: The natural history in postmenopausal women. Radiology 184 (1992) 653-659
21. Menon U., Talaat A., Rosenthal A.N., et al. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. BJOG 107 (2000) 165-169
22. Osmers R.G., Osmers M., von Maydell B., Wagner B., and Kuhn W. Preoperative evaluation of ovarian tumors in the premenopause by transvaginosonography. Am J Obstet Gynecol 175 (1996) 428-434
23. Modesitt S.C., Pavlik E.J., Ueland F.R., DePriest P.D., Kryscio R.J., and van Nagell Jr. J.R. Risk of malignancy in unilocular ovarian cystic tumors less than 10 centimeters in diameter. Obstet Gynecol 102 (2003) 594-599
24. Granberg S., Wikland M., and Jansson I. Macroscopic characterization of ovarian tumors and the relation to the histological diagnosis: Criteria to be used for ultrasound evaluation. Gynecol Oncol 35 (1989) 139-144
25. Ferrazzi E., Zanetta G., Dordoni D., Berlanda N., Mezzopane R., and Lissoni A.A. Transvaginal ultrasonographic characterization of ovarian masses: Comparison of five scoring systems in a multicenter study. Ultrasound Obstet Gynecol 10 (1997) 192-197
26. Lerner J.P., Timor-Tritsch I.E., Federman A., and Abramovich G. Transvaginal ultrasonographic characterization of ovarian masses with an improved, weighted scoring system. Am J Obstet Gynecol 170 (1994) 81-85
27. Mol B.W., Boll D., De Kanter M., et al. Distinguishing the benign and malignant adnexal mass: An external validation of prognostic models. Gynecol Oncol 80 (2001) 162-167
28. Sassone A.M., Timor-Tritsch I.E., Artner A., Westhoff C., and Warren W.B. Transvaginal sonographic characterization of ovarian disease: Evaluation of a new scoring system to predict ovarian malignancy. Obstet Gynecol 78 (1991) 70-76
29. Timmerman D., Bourne T.H., Tailor A., et al. A comparison of methods for preoperative discrimination between malignant and benign adnexal masses: The development of a new logistic regression model. Am J Obstet Gynecol 181 (1999) 57-65
30. Ueland F.R., DePriest P.D., Pavlik E.J., Kryscio R.J., and van Nagell Jr. J.R. Preoperative differentiation of malignant from benign ovarian tumors: The efficacy of morphology indexing and Doppler flow sonography. Gynecol Oncol 91 (2003) 46-50
31. Kurjak A., Shalan H., Kupesic S., et al. An attempt to screen asymptomatic women for ovarian and endometrial cancer with transvaginal color and pulsed Doppler sonography. J Ultrasound Med 13 (1994) 295-301
32. Vuento M.H., Pirhonen J.P., Makinen J.I., Laippala P.J., Gronroos M., and Salmi T.A. Evaluation of ovarian findings in asymptomatic postmenopausal women with color Doppler ultrasound. Cancer 76 (1995) 1214-1218
33. Bourne T.H., Campbell S., Reynolds K.M., et al. Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging. BMJ 306 (1993) 1025-1029
34. Parkes C.A., Smith D., Wald N.J., and Bourne T.H. Feasibility study of a randomised trial of ovarian cancer screening among the general population. J Med Screen 1 (1994) 209-214
35. Stein S.M., Laifer-Narin S., Johnson M.B., et al. Differentiation of benign and malignant adnexal masses: Relative value of gray-scale, color Doppler, and spectral Doppler sonography. AJR Am J Roentgenol 164 (1995) 381-386
36. Valentin L. Pattern recognition of pelvic masses by gray-scale ultrasound imaging: The contribution of Doppler ultrasound. Ultrasound Obstet Gynecol 14 (1999) 338-347
37. Guerriero S., Ajossa S., and Melis G. Is three-dimensional power Doppler ultrasound better than two-dimensional power Doppler?. Gynecol Oncol 84 (2002) 352-353
38. Testa A.C., Ajossa S., Ferrandina G., et al. Does quantitative analysis of three-dimensional power Doppler angiography have a role in the diagnosis of malignant pelvic solid tumors?. A preliminary study. Ultrasound Obstet Gynecol 26 (2005) 67-72
39. Guerriero S., Alcazar J.L., Ajossa S., et al. Comparison of conventional color Doppler imaging and power Doppler imaging for the diagnosis of ovarian cancer: Results of a European study. Gynecol Oncol 83 (2001) 299-304
40. Jacobs I.J., Skates S.J., MacDonald N., et al. Screening for ovarian cancer: A pilot randomised controlled trial. Lancet 353 (1999) 1207-1210
41. Skates S.J., Pauler D.K., and Jacobs I.J. Screening based on the risk of ovarian cancer calculation from bayesian hierarchical change point and mixture models of longitudinal markers. J Am Stat Assoc 96 (2001) 429-439
42. Bosse K., Rhiem K., Wappenschmidt B., et al. Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial predisposition: A prospective cohort study. Gynecol Oncol 103 (2006) 1077-1082
43. Oei A.L., Massuger L.F., Bulten J., Ligtenberg M.J., Hoogerbrugge N., and de Hullu J.A. Surveillance of women at high risk for hereditary ovarian cancer is inefficient. Br J Cancer 94 (2006) 814-819
44. Nossov V, Shapiro A, Li A, Leuchter R, Karlan B, Cass I. Jewish women are at higher risk for primary peritoneal carcinoma. Presented at the Annual Meeting of the Society for Gynecologic Oncology, 2007. San Diego, CA. March 2007.
45. Petricoin E.F., Zoon K.C., Kohn E.C., Barrett J.C., and Liotta L.A. Clinical proteomics: Translating benchside promise into bedside reality. Nat Rev Drug Discov 1 (2002) 683-695
46. Gray J.W., Suzuki S., Kuo W.L., et al. Specific keynote: Genome copy number abnormalities in ovarian cancer. Gynecol Oncol 88 (2003) S16-S21 discussion S22-4
47. Suzuki S., Moore II D.H., Ginzinger D.G., et al. An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer. Cancer Res 60 (2000) 5382-5385
48. Shayesteh L., Lu Y., Kuo W.L., et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21 (1999) 99-102
49. Wulfkuhle J.D., Aquino J.A., Calvert V.S., et al. Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics 3 (2003) 2085-2090
50. Wong A.S., Kim S.O., Leung P.C., Auersperg N., and Pelech S.L. Profiling of protein kinases in the neoplastic transformation of human ovarian surface epithelium. Gynecol Oncol 82 (2001) 305-311
51. Anderson N.L., Polanski M., Pieper R., et al. The human plasma proteome: A nonredundant list developed by combination of four separate sources. Mol Cell Proteomics 3 (2004) 311-326
52. Hellstrom I., Raycraft J., Hayden-Ledbetter M., et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 63 (2003) 3695-3700
53. Urban N. Specific keynote: Ovarian cancer risk assessment and the potential for early detection. Gynecol Oncol 88 (2003) S75-S79 discussion S80-3
54. Suzuki M., Ohwada M., Aida I., Tamada T., Hanamura T., and Nagatomo M. Macrophage colony-stimulating factor as a tumor marker for epithelial ovarian cancer. Obstet Gynecol 82 (1993) 946-950
55. Xu Y., Shen Z., Wiper D.W., et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 280 (1998) 719-723
56. Xu F.J., Ramakrishnan S., Daly L., et al. Increased serum levels of macrophage colony-stimulating factor in ovarian cancer. Am J Obstet Gynecol 165 (1991) 1356-1362
57. Chechlinska M., Kaminska J., Markowska J., Kramar A., and Steffen J. Peritoneal fluid cytokines and the differential diagnosis of benign and malignant ovarian tumors and residual/recurrent disease examination. Int J Biol Markers 22 (2007) 172-180
58. Woolas R.P., Conaway M.R., Xu F., et al. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol 59 (1995) 111-116
59. Zhang Z., Barnhill S.D., Zhang H., et al. Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. Gynecol Oncol 73 (1999) 56-61
60. Crump C., McIntosh M.W., Urban N., Anderson G., and Karlan B.Y. Ovarian cancer tumor marker behavior in asymptomatic healthy women: Implications for screening. Cancer Epidemiol Biomarkers Prev 9 (2000) 1107-1111
61. Lu K.H., Patterson A.P., Wang L., et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 10 (2004) 3291-3300
62. Zhang Z., Bast Jr. R.C., Yu Y., et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 64 (2004) 5882-5890
63. Leiser A., Visintin I., Alvero A., et al. Novel serum test for the early detection of ovarian cancer. Gynecol Oncol 104 (2007) S2-S35
64. Visintin I., Feng Z., Longton G., et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 14 (2008) 1065-1072
65. Kim J.H., Skates S.J., Uede T., et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 287 (2002) 1671-1679
66. Fedarko N.S., Jain A., Karadag A., Van Eman M.R., and Fisher L.W. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7 (2001) 4060-4066
67. Schorge J.O., Drake R.D., Lee H., et al. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clin Cancer Res 10 (2004) 3474-3478
68. Ye B., Cramer D.W., Skates S.J., et al. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: Identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res 9 (2003) 2904-2911
69. Rai A.J., Zhang Z., Rosenzweig J., et al. Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med 126 (2002) 1518-1526
70. Yu J.K., Zheng S., Tang Y., and Li L. An integrated approach utilizing proteomics and bioinformatics to detect ovarian cancer. J Zhejiang Univ Sci B 6 (2005) 227-231
71. Petricoin E.F., Ardekani A.M., Hitt B.A., et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359 (2002) 572-577
72. Conrads T.P., Fusaro V.A., Ross S., et al. High-resolution serum proteomic features for ovarian cancer detection. Endocr Relat Cancer 11 (2004) 163-178
73. Kozak K.R., Amneus M.W., Pusey S.M., et al. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: Potential use in diagnosis and prognosis. Proc Natl Acad Sci U S A 100 (2003) 12343-12348
74. Kozak K.R., Su F., Whitelegge J.P., Faull K., Reddy S., and Farias-Eisner R. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 5 (2005) 4589-4596
75. Mahlck C.G., and Grankvist K. Plasma prealbumin in women with epithelial ovarian carcinoma. Gynecol Obstet Invest 37 (1994) 135-140
76. Kuesel A.C., Kroft T., Prefontaine M., and Smith I.C. Lipoprotein(a) and CA125 levels in the plasma of patients with benign and malignant ovarian disease. Int J Cancer 52 (1992) 341-346
77. Gadomska H., Grzechocinska B., Janecki J., Nowicka G., Powolny M., and Marianowski L. Serum lipids concentration in women with benign and malignant ovarian tumours. Eur J Obstet Gynecol Reprod Biol 120 (2005) 87-90
78. Dionyssiou-Asteriou A., Papastamatiou M., Vatalas I.A., and Bastounis E. Serum apolipoprotein AI levels in atherosclerotic and diabetic patients. Eur J Vasc Endovasc Surg 24 (2002) 161-165
79. Feinleib M. On a possible inverse relationship between serum cholesterol and cancer mortality. Am J Epidemiol 114 (1981) 5-10
80. Sorlie P.D., and Fienleib M. The serum cholesterol-cancer relationship: an analysis of time trends in the Framingham Study. J Natl Cancer Inst 69 (1982) 989-996
81. Williams R.R., Sorlie P.D., Feinleib M., McNamara P.M., Kannel W.B., and Dawber T.R. Cancer incidence by levels of cholesterol. JAMA 245 (1981) 247-252
82. Janero D.R. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radic Biol Med 9 (1990) 515-540
83. Klaunig J.E., and Kamendulis L.M. The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 44 (2004) 239-267
84. Cvetkovic D., Williams S.J., and Hamilton T.C. Loss of cellular retinol-binding protein 1 gene expression in microdissected human ovarian cancer. Clin Cancer Res 9 (2003) 1013-1020
85. Corti M.C., Gaziano M., and Hennekens C.H. Iron status and risk of cardiovascular disease. Ann Epidemiol 7 (1997) 62-68
86. Dumaswala U.J., Wilson M.J., Wu Y.L., et al. Glutathione loading prevents free radical injury in red blood cells after storage. Free Radic Res 33 (2000) 517-529
87. Dreher D., and Junod A.F. Role of oxygen free radicals in cancer development. Eur J Cancer 32A (1996) 30-38
88. Kang D.H. Oxidative stress, DNA damage, and breast cancer. AACN Clin Issues 13 (2002) 540-549
89. Valko M., Izakovic M., Mazur M., Rhodes C.J., and Telser J. Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem 266 (2004) 37-56
90. Valko M., Rhodes C.J., Moncol J., Izakovic M., and Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 160 (2006) 1-40
91. Su F., Lang J., Kumar A., et al. Validation of candidate serum ovarian cancer biomarkers for early detection. Biomark Insights (2007) 269-375
92. Diamandis E.P. Point: Proteomic patterns in biological fluids: Do they represent the future of cancer diagnostics?. Clin Chem 49 (2003) 1272-1275
93. Chan K., Lucas D., and Hise D. Analysis of the human serum proteome. Clinical Proteomics (2004) 101-226
94. Benjapibal M., and Neungton C. Pre-operative prediction of serum CA125 level in women with ovarian masses. J Med Assoc Thai 90 (2007) 1986-1991
95. Kupesic S., and Plavsic B.M. Early ovarian cancer: 3-D power Doppler. Abdom Imaging 31 (2006) 613-619